Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A team of experts on acute promyelocytic leukemia (APL) were available by phone or email to other oncologists treating this rare cancer.
Approved for CLL and SLL—types of leukemia and lymphoma—Brukinsa caused fewer heart-related side effects in trials.
Immunotherapy drug Blincyto extends life for those with acute lymphoblastic leukemia (ALL) in remission
The Dana-Farber led ALPINE trial looked at the drug in relapsed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Immunotherapy leads the way, along with promising breakthroughs for treating leukemia and multiple myeloma.
Mosunetuzumab is the first bispecific antibody, a type of immunotherapy, approved to treat non-Hodgkin lymphoma.
Targeted therapy combo sent chronic lymphocytic leukemia into deep remission in people with high-risk forms of the disease.
The test shows which patients with clonal hematopoiesis, a precancerous state, are more likely to develop blood cancers.
Customized T-cell treatment is generally safe for people living with HIV, and outcomes are comparable to those of HIV-negative people.
People who followed a protective diet and those on a standard hospital diet had a similar likelihood of infections.
The newer targeted therapy zanubrutinib works better and has fewer side effects than the older ibrutinib.
Axicabtagene ciloleucel (Yescarta) showed encouraging signs of efficacy against central nervous system tumors in a small pilot trial.
Study clarifies molecular pathways by which CLL transform into a more aggressive type of lymphoma.
Research at #ASH22 calls into question longstanding assumptions and charts a path for gentler therapies.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.